Bosch Roig Carlos E, Roselló-Sastre Ester, Alonso Hernández Sonia, Almenar Cubells Daniel, Grau Cardona Enrique, Camarasa Lillo Natalia, Bautista Daniel, Molins Palau Carmen
Medical Oncology Unit, Dr. Peset University Hospital, Valencia, Spain.
Clin Transl Oncol. 2008 Sep;10(9):572-8. doi: 10.1007/s12094-008-0252-9.
A study is made of the clinical repercussions of occult metastases-micrometastases (MMs+)-or isolated tumour cells (ITCs+) in the lymph nodes of patients with stage IIA and IIB colon adenocarcinoma initially considered as corresponding to N0.
A retrospective study of 39 patients with stage IIA and IIB (T3-T4 N0 M0) colon adenocarcinoma, subjected to similar surgical and adjuvant chemotherapy treatment, with long and careful follow-up (minimum: 5 years, mean: 81.7 months) was performed on their previously resected lymph nodes, with the aid of new histological and immunohistochemical (cytokeratin) sections, in order to detect MMs or ITCs. Disease-free survival (DFS) and global survival (GS) in the two groups (patients with MMs+ or ITCs+ vs. patients without MMs or ITCs) were compared at 5 years based on the corresponding Kaplan-Meier survival curves, with the Breslow test.
A total of 382 lymph nodes from the 39 patients (mean: 9.8; standard deviation: 6.09) were revised. MMs+ were detected in 2 cases and ITCs+ in 2 more cases on the Cytokeratin study. GS of the whole series at 5 years was 89.74% (35 patients alive) with a DFS at 5 years of 79.49% (31 patients free of disease), but the 2 cases with MMs+ were dead at 5 years, with high statistical differences between both groups (MMs+/MMs-) (p<0.0001). When comparing the group of MMs+/ITCs+ patients and the group of MM-/ITCs- patients, the DFS and GS times at 5 years were higher in the MMs-/ITCs- group (p=0.0692 and p=0.006 respectively).
Although the incidence of MMs+ or ITCs+ in the examined lymph nodes was low, the presence of MMs is related to a dramatic reduction in GS and DFS at 5 years. We encourage a detailed histological study of lymph nodes resected in patients with deep penetrating colon tumours in order to assure a pN0 status.
对最初被认为N0的IIA期和IIB期结肠腺癌患者淋巴结中的隐匿性转移灶 - 微转移灶(MMs+)或孤立肿瘤细胞(ITCs+)的临床影响进行研究。
对39例IIA期和IIB期(T3 - T4 N0 M0)结肠腺癌患者进行回顾性研究,这些患者接受了相似的手术和辅助化疗治疗,并对其先前切除的淋巴结进行了长期且仔细的随访(最短:5年,平均:81.7个月),借助新的组织学和免疫组织化学(细胞角蛋白)切片来检测MMs或ITCs。根据相应的Kaplan - Meier生存曲线,采用Breslow检验比较两组(MMs+或ITCs+患者与无MMs或ITCs患者)5年时的无病生存期(DFS)和总生存期(GS)。
对39例患者的总共382个淋巴结(平均:9.8;标准差:6.09)进行了检查。在细胞角蛋白研究中,检测到2例MMs+,另外2例ITCs+。整个系列5年时的GS为89.74%(35例存活),5年时的DFS为79.49%(31例无疾病),但2例MMs+患者在5年时死亡,两组(MMs+/MMs-)之间存在高度统计学差异(p<0.0001)。比较MMs+/ITCs+患者组和MM-/ITCs-患者组时,MM-/ITCs-组5年时的DFS和GS时间更高(分别为p = 0.0692和p = 0.006)。
尽管在所检查的淋巴结中MMs+或ITCs+的发生率较低,但MMs的存在与5年时GS和DFS的显著降低有关。我们鼓励对深部浸润性结肠肿瘤患者切除的淋巴结进行详细的组织学研究,以确保pN0状态。